| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yuan-Ling Tang, Dan-Dan Li, Jia-Yu Duan, Lei-Ming Sheng and Xin Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82073338 |
| Sichuan Science and Technology Support Project |
2021YFSY0039 |
| Sichuan Science and Technology Support Project |
22ZDYF0499 |
| the 1·3·5 Project for Disciplines of Excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University |
2020HXFH002 |
| the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University |
ZYJC21059 |
|
| Corresponding Author |
Xin Wang, MD, PhD, Doctor, Doctor, Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, Sichuan Province, China. 2079248480@qq.com |
| Key Words |
Colorectal cancer; Targeted treatment; Resistance; New development |
| Core Tip |
Colorectal cancer (CRC) is one of the most lethal and common malignancies in the world. Chemotherapy has long been the mainstay of CRC treatment. However, since chemotherapy is not a specific regimen, it will produce systemic toxicity. Following, with the advent of targeted therapy, the prognosis of CRC has been improved significantly. Although targeted therapy also develop drug resistance, more and more novel targets and combination regimens are being explored over the past 20 years. In this review, we summarized resistance to exiting targeted therapy, and discussed future developments in CRC. |
| Publish Date |
2023-02-10 09:15 |
| Citation |
Tang YL, Li DD, Duan JY, Sheng LM, Wang X. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World J Gastroenterol 2023; 29(6): 926-948 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i6/926.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i6.926 |
